FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W193041208> ?p ?o ?g. }

• W193041208 endingPage "716" @default.
• W193041208 startingPage "699" @default.
• W193041208 abstract "The anti-interleukin-2 receptor (anti-IL-2R) antibody therapy is an exciting approach to the prevention of acute rejection after renal allograft transplantation whereby immunosuppression is exerted by a selective and competitive inhibition of IL-2-induced T cell proliferation, a critical pathway of allorecognition. The anti-IL-2R antibodies specifically block the alpha-subunit of the IL-2R on activated T cells, and prevent T cell proliferation and activation of the effector arms of the immune system. The anti-IL-2R antibodies are used as induction therapy, immediately after renal transplantation, for prevention of acute cellular rejection in children and adults. During acute rejection, the IL-2Ralpha chain is no longer expressed on T cells; thus, the antibodies cannot be used to treat an existing acute rejection. Two anti-IL-2R monoclonal antibodies are currently in clinical use: daclizumab and basiliximab. In placebo-controlled phase III clinical trials in adults, daclizumab and basiliximab in combination with calcineurin inhibitor-based immunosuppression, significantly reduced the incidence of acute rejection and corticosteroid-resistant acute rejection without increasing the risk of infectious or malignant complications, and neither antibody was associated with the cytokine-release syndrome. Children who receive calcineurin inhibitors and corticosteroids for maintenance immunosuppression, as well as children who receive augmented immunosuppression to treat acute rejection, are at increased risk of growth impairment, hypertension, hyperlipidemia, lymphoproliferative disorders, diabetes mellitus, and cosmetic changes. In older children, the cosmetic adverse effects frequently reduce compliance with the treatment, and subsequently increase the risk of allograft loss. Being effective and well tolerated in children, the anti-IL-2R antibodies reduce the need for calcineurin inhibitors while maintaining the overall efficacy of the regimen; thus, the anti-IL-2R antibodies increase the safety margin (less toxicity, fewer adverse effects) of the baseline immunosuppression. Secondly, the anti-IL-2R antibodies decrease the need for corticosteroids and muromonab CD3 (OKT3) in children as a result of decreased incidence of acute rejection. The recommended pediatric dose of daclizumab is 1 mg/kg intravenously every 14 days for five doses, with the first dose administered within 24 hours pre-transplantation. This administration regimen maintains daclizumab levels necessary to completely saturate the IL-2Ralpha (5-10 microg/mL) in children for at least 12 weeks.The recommended pediatric dose of basiliximab for recipients <35 kg is 10 mg, and 20 mg for recipients > or =35 kg, intravenously on days 0 and 4 post-transplantation. This administration regimen maintains basiliximab levels necessary to completely saturate the IL-2Ralpha (>0.2 microg/mL) in children for at least 3 weeks." @default.
• W193041208 created "2016-06-24" @default.
• W193041208 creator A5013185400 @default.
• W193041208 date "2003-01-01" @default.
• W193041208 modified "2023-10-16" @default.
• W193041208 title "Anti-Interleukin-2 Receptor Antibodies for the Prevention of Rejection in Pediatric Renal Transplant Patients" @default.
• W193041208 cites W1489736851 @default.
• W193041208 cites W1756759934 @default.
• W193041208 cites W1966620676 @default.
• W193041208 cites W1968495675 @default.
• W193041208 cites W1974465685 @default.
• W193041208 cites W1976692326 @default.
• W193041208 cites W1985137297 @default.
• W193041208 cites W1986010227 @default.
• W193041208 cites W1990626857 @default.
• W193041208 cites W1991688431 @default.
• W193041208 cites W1993758901 @default.
• W193041208 cites W1995193364 @default.
• W193041208 cites W1996020835 @default.
• W193041208 cites W1996187503 @default.
• W193041208 cites W2000770163 @default.
• W193041208 cites W2016583461 @default.
• W193041208 cites W2019306593 @default.
• W193041208 cites W2021643051 @default.
• W193041208 cites W2023095312 @default.
• W193041208 cites W2029116084 @default.
• W193041208 cites W2029805256 @default.
• W193041208 cites W2029828413 @default.
• W193041208 cites W2030352916 @default.
• W193041208 cites W2031727025 @default.
• W193041208 cites W2034323699 @default.
• W193041208 cites W2034990267 @default.
• W193041208 cites W2043666407 @default.
• W193041208 cites W2044210603 @default.
• W193041208 cites W2045966506 @default.
• W193041208 cites W2047179014 @default.
• W193041208 cites W2047723007 @default.
• W193041208 cites W2050766673 @default.
• W193041208 cites W2052116969 @default.
• W193041208 cites W2052150715 @default.
• W193041208 cites W2056779748 @default.
• W193041208 cites W2056868560 @default.
• W193041208 cites W2056924500 @default.
• W193041208 cites W2064032386 @default.
• W193041208 cites W2065459312 @default.
• W193041208 cites W2070224385 @default.
• W193041208 cites W2071958892 @default.
• W193041208 cites W2072030208 @default.
• W193041208 cites W2074833999 @default.
• W193041208 cites W2083785828 @default.
• W193041208 cites W2085971634 @default.
• W193041208 cites W2091201626 @default.
• W193041208 cites W2095107584 @default.
• W193041208 cites W2108647254 @default.
• W193041208 cites W2113210002 @default.
• W193041208 cites W2123720448 @default.
• W193041208 cites W2124439789 @default.
• W193041208 cites W2125458260 @default.
• W193041208 cites W2134205675 @default.
• W193041208 cites W2142206343 @default.
• W193041208 cites W2143856606 @default.
• W193041208 cites W2144700815 @default.
• W193041208 cites W2147641595 @default.
• W193041208 cites W2147709052 @default.
• W193041208 cites W2160917955 @default.
• W193041208 cites W2161825022 @default.
• W193041208 cites W2170783570 @default.
• W193041208 cites W2172523660 @default.
• W193041208 cites W2269818016 @default.
• W193041208 cites W2315159879 @default.
• W193041208 cites W2327891619 @default.
• W193041208 cites W2333378480 @default.
• W193041208 cites W2341259055 @default.
• W193041208 cites W2402589934 @default.
• W193041208 cites W2409876389 @default.
• W193041208 cites W2414844717 @default.
• W193041208 cites W2462474754 @default.
• W193041208 cites W2471116616 @default.
• W193041208 cites W2582906781 @default.
• W193041208 cites W2990776223 @default.
• W193041208 cites W3026264292 @default.
• W193041208 cites W40075560 @default.
• W193041208 cites W4231219691 @default.
• W193041208 cites W4233298376 @default.
• W193041208 cites W4247193560 @default.
• W193041208 cites W4247783454 @default.
• W193041208 cites W4301240852 @default.
• W193041208 cites W68282923 @default.
• W193041208 doi "https://doi.org/10.2165/00148581-200305100-00005" @default.
• W193041208 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/14510627" @default.
• W193041208 hasPublicationYear "2003" @default.
• W193041208 type Work @default.
• W193041208 sameAs 193041208 @default.
• W193041208 citedByCount "31" @default.
• W193041208 countsByYear W1930412082013 @default.
• W193041208 countsByYear W1930412082014 @default.
• W193041208 countsByYear W1930412082016 @default.
• W193041208 countsByYear W1930412082019 @default.

• next